nivolumab + S-1 + oxaliplatin

This is a **three-drug combination regimen** consisting of nivolumab, S-1, and oxaliplatin. - **Nivolumab** is a monoclonal antibody checkpoint inhibitor targeting programmed death-1 (PD-1), enhancing T-cell mediated anti-tumor response. - **S-1** is an oral fluoropyrimidine anti-cancer agent (tegafur-gimeracil-oteracil potassium) that inhibits DNA synthesis in dividing tumor cells. - **Oxaliplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and cell death. This regimen is investigated and used primarily as first-line treatment for **HER2-negative, unresectable or recurrent advanced gastric/gastroesophageal junction (G/GEJ) cancer**, with demonstrated clinical efficacy and a manageable safety profile, as shown in ATTRACTION-4, a pivotal phase II/III trial[1][2][3][6].

Other names

nivolumab plus S-1 and oxaliplatinnivolumab + SOXSOX plus nivolumab